|
[1]
|
王裕新, 潘凯枫, 李文庆. 2022全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2024, 10(3): 1-16.
|
|
[2]
|
Matoda, M., Tanigawa, T., Omatsu, K., Ushioda, N., Yamamoto, A., Okamoto, S., et al. (2013) Platinum-Free Interval in Second-Line Chemotherapy for Recurrent Cervical Cancer. International Journal of Gynecological Cancer, 23, 1670-1674.
https://doi.org/10.1097/igc.0b013e3182a80a07
|
|
[3]
|
National Comprehensive Cancer Network (NCCN) (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Cervical Cancer, Version 2.2026.
https://nccnchina.org.cn/guide/detail/989
|
|
[4]
|
Kitagawa, R., Katsumata, N., Shibata, T., Kamura, T., Kasamatsu, T., Nakanishi, T., et al. (2015) Paclitaxel plus Carboplatin versus Paclitaxel plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. Journal of Clinical Oncology, 33, 2129-2135.
https://doi.org/10.1200/jco.2014.58.4391
|
|
[5]
|
Chou, T.-., Motzer, R.J., Tong, Y. and Bosl, G.J. (1994) Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin against Human Teratocarcinoma Cell Growth: A Rational Approach to Clinical Protocol Design. JNCI Journal of the National Cancer Institute, 86, 1517-1524.
https://doi.org/10.1093/jnci/86.20.1517
|
|
[6]
|
Fiorica, J., Holloway, R., Ndubisi, B., Orr, J., Grendys, E., Boothby, R., et al. (2002) Phase II Trial of Topotecan and Cisplatin in Persistent or Recurrent Squamous and Nonsquamous Carcinomas of the Cervix. Gynecologic Oncology, 85, 89-94.
https://doi.org/10.1006/gyno.2001.6557
|
|
[7]
|
Brave, M., Dagher, R., Farrell, A., et al. (2006) Topotecan in Combination with Cisplatin for the Treatment of Stage IVB, Recurrent, or Persistent Cervical Cancer. Oncology (Williston Park), 20, 1401-1404, 1410.
|
|
[8]
|
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., et al. (2006) Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel. Clinical Cancer Research, 12, 1317-1324.
https://doi.org/10.1158/1078-0432.ccr-05-1634
|
|
[9]
|
Liu, Y., Fang, S.S., Zhao, R.S., Liu, B., Jin, Y. and Li, Q. (2024) Nab-Paclitaxel plus Platinum versus Paclitaxel plus Platinum as First-Line Therapy in Patients with Metastatic or Recurrent Cervical Cancer. Journal of Cancer Research and Clinical Oncology, 150, Article No. 321.
https://doi.org/10.1007/s00432-024-05825-z
|
|
[10]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
|
[11]
|
张炜佳, 徐明洋, 赵岳. VEGF-A和Ang2对肿瘤血管生成及免疫细胞的影响[J]. 肿瘤预防与治疗, 2025, 38(9): 835-844.
|
|
[12]
|
Tewari, K.S., Sill, M.W., Long, H.J., Penson, R.T., Huang, H., Ramondetta, L.M., et al. (2014) Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine, 370, 734-743.
https://doi.org/10.1056/nejmoa1309748
|
|
[13]
|
Tewari, K.S., Sill, M.W., Penson, R.T., Huang, H., Ramondetta, L.M., Landrum, L.M., et al. (2017) Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240). The Lancet, 390, 1654-1663.
https://doi.org/10.1016/s0140-6736(17)31607-0
|
|
[14]
|
Penson, R.T., Huang, H.Q., Wenzel, L.B., Monk, B.J., Stockman, S., Long, H.J., et al. (2015) Bevacizumab for Advanced Cervical Cancer: Patient-Reported Outcomes of a Randomised, Phase 3 Trial (NRG Oncology-Gynecologic Oncology Group Protocol 240). The Lancet Oncology, 16, 301-311.
https://doi.org/10.1016/s1470-2045(15)70004-5
|
|
[15]
|
Chuai, Y., Rizzuto, I., Zhang, X., Li, Y., Dai, G., Otter, S.J., et al. (2021) Vascular Endothelial Growth Factor (VEGF) Targeting Therapy for Persistent, Recurrent, or Metastatic Cervical Cancer. Cochrane Database of Systematic Reviews, 2021, CD013348.
https://doi.org/10.1002/14651858.cd013348.pub2
|
|
[16]
|
Lan, C., Shen, J., Wang, Y., Li, J., Liu, Z., He, M., et al. (2020) Camrelizumab plus Apatinib in Patients with Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 38, 4095-4106.
https://doi.org/10.1200/jco.20.01920
|
|
[17]
|
Monk, B.J., Mas Lopez, L., Zarba, J.J., Oaknin, A., Tarpin, C., Termrungruanglert, W., et al. (2010) Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared with Pazopanib plus Lapatinib Combination Therapy in Patients with Advanced and Recurrent Cervical Cancer. Journal of Clinical Oncology, 28, 3562-3569.
https://doi.org/10.1200/jco.2009.26.9571
|
|
[18]
|
杨莉, 程玺. 宫颈癌分子靶向治疗的研究进展[J]. 中国癌症杂志, 2015, 25(1): 73-80.
|
|
[19]
|
Pignata, S., Scambia, G., Lorusso, D., De Giorgi, U., Nicoletto, M.O., Lauria, R., et al. (2019) The MITO CERV-2 Trial: A Randomized Phase II Study of Cetuximab plus Carboplatin and Paclitaxel, in Advanced or Recurrent Cervical Cancer. Gynecologic Oncology, 153, 535-540.
https://doi.org/10.1016/j.ygyno.2019.03.260
|
|
[20]
|
Santin, A.D., Sill, M.W., McMeekin, D.S., Leitao, M.M., Brown, J., Sutton, G.P., et al. (2011) Phase II Trial of Cetuximab in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Gynecologic Oncology, 122, 495-500.
https://doi.org/10.1016/j.ygyno.2011.05.040
|
|
[21]
|
Kurtz, J.E., Hardy-Bessard, A.C., Deslandres, M., Lavau-Denes, S., Largillier, R., Roemer-Becuwe, C., et al. (2009) Cetuximab, Topotecan and Cisplatin for the Treatment of Advanced Cervical Cancer: A Phase II GINECO Trial. Gynecologic Oncology, 113, 16-20.
https://doi.org/10.1016/j.ygyno.2008.12.040
|
|
[22]
|
Farley, J., Sill, M.W., Birrer, M., Walker, J., Schilder, R.J., Thigpen, J.T., et al. (2011) Phase II Study of Cisplatin plus Cetuximab in Advanced, Recurrent, and Previously Treated Cancers of the Cervix and Evaluation of Epidermal Growth Factor Receptor Immunohistochemical Expression: A Gynecologic Oncology Group Study. Gynecologic Oncology, 121, 303-308.
https://doi.org/10.1016/j.ygyno.2011.01.030
|
|
[23]
|
Fracasso, P.M., Duska, L.R., Thaker, P.H., Gao, F., Zoberi, I., Dehdashti, F., et al. (2022) An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women with Newly Diagnosed Locally Advanced Cervical Cancer. American Journal of Clinical Oncology, 45, 286-293.
https://doi.org/10.1097/coc.0000000000000926
|
|
[24]
|
Cetina, L., Crombet, T., Jiménez-Lima, R., Zapata, S., Ramos, M., Avila, S., et al. (2015) A Pilot Study of Nimotuzumab plus Single Agent Chemotherapy as Second-or Third-Line Treatment or More in Patients with Recurrent, Persistent or Metastatic Cervical Cancer. Cancer Biology & Therapy, 16, 684-689.
https://doi.org/10.1080/15384047.2015.1026483
|
|
[25]
|
Shi, M. and Zhang, Y. (2024) Efficacy of Nimotuzumab in Combination with Immunotherapy for a Young Recurrent Cervical Cancer Patient: A Case Report and Literature Review. Anti-Cancer Drugs, 35, 644-652.
https://doi.org/10.1097/cad.0000000000001611
|
|
[26]
|
Goncalves, A., Fabbro, M., Lhommé, C., Gladieff, L., Extra, J., Floquet, A., et al. (2008) A Phase II Trial to Evaluate Gefitinib as Second-or Third-Line Treatment in Patients with Recurring Locoregionally Advanced or Metastatic Cervical Cancer. Gynecologic Oncology, 108, 42-46.
https://doi.org/10.1016/j.ygyno.2007.07.057
|
|
[27]
|
Sharma, D.N., Rath, G.K., Julka, P.K., Gandhi, A.K., Jagadesan, P. and Kumar, S. (2013) Role of Gefitinib in Patients with Recurrent or Metastatic Cervical Carcinoma Ineligible or Refractory to Systemic Chemotherapy: First Study from Asia. International Journal of Gynecological Cancer, 23, 705-709.
https://doi.org/10.1097/igc.0b013e31828b1699
|
|
[28]
|
Krishna, A., Sathya, M., Mukesh, S., Athiyamaan, M.S., Banerjee, S., Sunny, J., et al. (2023) Efficacy and Safety of EGFR Inhibitor Gefitinib in Recurrent or Metastatic Cervical Cancer: A Preliminary Report. Medical Oncology, 40, Article No. 203.
https://doi.org/10.1007/s12032-023-02070-1
|
|
[29]
|
Woodworth, C.D., Diefendorf, L.P., Jette, D.F., Mohammed, A., Moses, M.A., Searleman, S.A., et al. (2011) Inhibition of the Epidermal Growth Factor Receptor by Erlotinib Prevents Immortalization of Human Cervical Cells by Human Papillomavirus Type 16. Virology, 421, 19-27.
https://doi.org/10.1016/j.virol.2011.09.014
|
|
[30]
|
Schilder, R.J., Sill, M.W., Lee, Y. and Mannel, R. (2009) A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. International Journal of Gynecological Cancer, 19, 929-933.
https://doi.org/10.1111/igc.0b013e3181a83467
|
|
[31]
|
Callegaro-Filho, D., Kavanagh, J.J., Nick, A.M., Ramirez, P.T. and Schmeler, K.M. (2014) Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases. Case Reports in Oncology, 7, 97-101.
https://doi.org/10.1159/000358916
|
|
[32]
|
Wang, L., Hou, X., Huang, M., He, B., Mao, L., Hu, Z., et al. (2025) Design, Synthesis and Anti-Cancer Activity of Novel 1,2,3-Triazole Hybrids of Erlotinib against Cervical Cancer via MAPK Signaling Pathway. Scientific Reports, 15, Article No. 24582.
https://doi.org/10.1038/s41598-025-09168-8
|
|
[33]
|
Bertelsen, B.I., Steine, S.J., Sandvei, R., Molven, A. and Laerum, O.D. (2006) Molecular Analysis of the PI3K‐AKT Pathway in Uterine Cervical Neoplasia: Frequent pik3ca Amplification and AKT Phosphorylation. International Journal of Cancer, 118, 1877-1883.
https://doi.org/10.1002/ijc.21461
|
|
[34]
|
Tinker, A.V., Ellard, S., Welch, S., Moens, F., Allo, G., Tsao, M.S., et al. (2013) Phase II Study of Temsirolimus (CCI-779) in Women with Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix. a Trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecologic Oncology, 130, 269-274.
https://doi.org/10.1016/j.ygyno.2013.05.008
|
|
[35]
|
Tinker, A., MacKay, H., Ellard, S., Welch, S. and Eisenhauer, E. (2011) Abstract C69: Preliminary Activity of Temsirolimus, an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix: An NCIC-CTG Phase II Clinical Trial. Molecular Cancer Therapeutics, 10, C69-C69.
https://doi.org/10.1158/1535-7163.targ-11-c69
|
|
[36]
|
张佳和, 胡康, 杨子科, 等. X射线照射联合Veliparib诱导小鼠乳腺癌细胞衰老的相关研究[J]. 中华肿瘤防治杂志, 2016, 23(17): 1141-1148.
|
|
[37]
|
Thaker, P.H., Salani, R., Brady, W.E., Lankes, H.A., Cohn, D.E., Mutch, D.G., et al. (2017) A Phase I Trial of Paclitaxel, Cisplatin, and Veliparib in the Treatment of Persistent or Recurrent Carcinoma of the Cervix: An NRG Oncology Study (NCT#01281852). Annals of Oncology, 28, 505-511.
https://doi.org/10.1093/annonc/mdw635
|
|
[38]
|
Kunos, C., Deng, W., Dawson, D., Lea, J.S., Zanotti, K.M., Gray, H.J., et al. (2015) A Phase I-II Evaluation of Veliparib (NSC#737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study. International Journal of Gynecological Cancer, 25, 484-492.
https://doi.org/10.1097/igc.0000000000000380
|
|
[39]
|
Tomao, F., Santangelo, G., Musacchio, L., Di Donato, V., Fischetti, M., Giancotti, A., et al. (2020) Targeting Cervical Cancer: Is There a Role for Poly (ADP‐Ribose) Polymerase Inhibition? Journal of Cellular Physiology, 235, 5050-5058.
https://doi.org/10.1002/jcp.29440
|
|
[40]
|
吕加金, 冯秀秀, 李玉凡, 等. 宫颈癌免疫治疗的研究进展[J]. 系统医学, 2023, 8(1): 194-198.
|
|
[41]
|
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al. (2019) Role of the Tumor Microenvironment in PD-L1/PD-1-Mediated Tumor Immune Escape. Molecular Cancer, 18, Article No. 10.
https://doi.org/10.1186/s12943-018-0928-4
|
|
[42]
|
Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249.
https://doi.org/10.1146/annurev-pathol-042020-042741
|
|
[43]
|
Colombo, N., Dubot, C., Lorusso, D., Caceres, M.V., Hasegawa, K., Shapira-Frommer, R., et al. (2021) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. New England Journal of Medicine, 385, 1856-1867.
https://doi.org/10.1056/nejmoa2112435
|
|
[44]
|
Monk, B.J., Colombo, N., Tewari, K.S., Dubot, C., Caceres, M.V., Hasegawa, K., et al. (2023) First-Line Pembrolizumab + Chemotherapy versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology, 41, 5505-5511.
https://doi.org/10.1200/jco.23.00914
|
|
[45]
|
Monk, B.J., Tewari, K.S., Dubot, C., Caceres, M.V., Hasegawa, K., Shapira-Frommer, R., et al. (2023) Health-Related Quality of Life with Pembrolizumab or Placebo plus Chemotherapy with or without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 24, 392-402.
https://doi.org/10.1016/s1470-2045(23)00052-9
|
|
[46]
|
Lorusso, D., Colombo, N., Dubot, C., Cáceres, M.V., Hasegawa, K., Shapira-Frommer, R., et al. (2025) Pembrolizumab plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study. Annals of Oncology, 36, 65-75.
https://doi.org/10.1016/j.annonc.2024.10.002
|
|
[47]
|
Oaknin, A., Gladieff, L., Martínez-García, J., et al. (2024) Atezolizumab plus Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer (BEATcc): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 403, 31-43.
|
|
[48]
|
郝晓慧, 张志林, 卢秀荣, 等. 信迪利单抗静注联合全身化疗治疗复发转移宫颈癌的临床疗效观察[J]. 山东医药, 2022, 62(5): 78-81.
|
|
[49]
|
何端端, 韩衍永. 信迪利单抗联合含卡铂化疗方案治疗复发转移性宫颈癌的近期疗效[J]. 临床合理用药, 2024, 17(18): 125-128.
|
|
[50]
|
冯成军, 张日光, 韦蒙专. 信迪利单抗联合同步放化疗对晚期宫颈癌患者肿瘤标志物及程序性死亡受体-1/程序性死亡配体1的影响[J]. 中华实用诊断与治疗杂志, 2022, 36(7): 740-743.
|
|
[51]
|
唐江月, 王琳, 张婧, 等. 信迪利单抗联合调强适形放疗和化疗对晚期宫颈癌患者的临床疗效和安全性评价[J]. 中国药师, 2023, 26(12): 456-464.
|
|
[52]
|
Xu, Q., Wang, J., Sun, Y., Lin, Y., Liu, J., Zhuo, Y., et al. (2022) Efficacy and Safety of Sintilimab plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. Journal of Clinical Oncology, 40, 1795-1805.
https://doi.org/10.1200/jco.21.02091
|
|
[53]
|
Liu, J., Lan, C., Liu, T., Liu, Q., Chang, L., Zang, L., et al. (2025) Long-Term Efficacy and Updated Survival Outcomes of Sintilimab plus Anlotinib in Patients with PD-L1-Positive Recurrent or Metastatic Cervical Cancer. BMC Medicine, 23, Article No. 369.
https://doi.org/10.1186/s12916-025-04198-5
|
|
[54]
|
Wang, Y., Zhao, J., Liang, H., Liu, J., Huang, S., Zou, G., et al. (2023) Efficacy and Safety of Sintilimab plus Albumin-Bound-Paclitaxel in Recurrent or Metastatic Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Trial. eClinicalMedicine, 65, Article ID: 102274.
https://doi.org/10.1016/j.eclinm.2023.102274
|
|
[55]
|
陈苹, 岳青芬, 李晓宁. 信迪利单抗与贝伐珠单抗联合紫杉醇加顺铂方案治疗晚期宫颈癌的疗效观察[J]. 中国合理用药探索, 2025, 22(5): 49-54.
|
|
[56]
|
Xia, L., Zhang, K., Tang, Y., Zhang, G., Wang, D., Lou, H., et al. (2025) Camrelizumab plus Famitinib versus Camrelizumab Alone and Investigator’s Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. Journal of Clinical Oncology, 43, 2720-2733.
https://doi.org/10.1200/jco-24-02495
|
|
[57]
|
范素梅, 信聪伶, 朱来芳, 等. 卡瑞利珠单抗联合化疗及靶向治疗在复发、转移及初治晚期宫颈癌中的疗效与安全性分析: 一项回顾性队列研究[J]. 中国癌症杂志, 2025, 35(6): 570-577.
|
|
[58]
|
Mi, X., Tuo, F. and Lin, T. (2024) Efficacy and Safety of Camrelizumab for the Treatment of Cervical Cancer: A Systematic Review and Meta-analysis. Frontiers in Oncology, 14, Article ID: 1526103.
https://doi.org/10.3389/fonc.2024.1526103
|
|
[59]
|
Naumann, R.W., Hollebecque, A., Meyer, T., Devlin, M., Oaknin, A., Kerger, J., et al. (2019) Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results from the Phase I/II CheckMate 358 Trial. Journal of Clinical Oncology, 37, 2825-2834.
https://doi.org/10.1200/jco.19.00739
|
|
[60]
|
Oaknin, A., Moore, K., Meyer, T., López-Picazo González, J., Devriese, L.A., Amin, A., et al. (2024) Nivolumab with or without Ipilimumab in Patients with Recurrent or Metastatic Cervical Cancer (checkmate 358): A Phase 1-2, Open-Label, Multicohort Trial. The Lancet Oncology, 25, 588-602.
https://doi.org/10.1016/s1470-2045(24)00088-3
|
|
[61]
|
Schenker, M., Burotto, M., Richardet, M., Ciuleanu, T., Gonçalves, A., Steeghs, N., et al. (2024) Randomized, Open-Label, Phase 2 Study of Nivolumab plus Ipilimumab or Nivolumab Monotherapy in Patients with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden. Journal for ImmunoTherapy of Cancer, 12, e008872.
https://doi.org/10.1136/jitc-2024-008872
|